Novo Nordisk CEO Lars Jorgensen will appear before the US Senate Health, Education, Labor and Pensions Committee at a hearing next September. The session will address the pricing of weight loss drugs Ozempic and Wegovy in the United States.
The Committee announced today that Jorgensen has agreed to testify voluntarily. This upcoming hearing is part of the research being conducted in the pharmaceutical industry, especially as it relates to the costs of prescription drugs to consumers.
Ozempic and Wegovy, two drugs produced by Novo Nordisk, have been in the spotlight for their high costs. The Senate hearing is intended to explore pricing strategies and factors that contribute to the price levels of these drugs.
The testimony of Novo Nordisk’s CEO is expected to provide insight into the company’s pricing decisions and potentially influence future policy decisions regarding drug pricing regulations. The company, listed on the New York Stock Exchange under the ticker NYSE:NVO, is a key player in the global pharmaceutical market, making this testimony important to both stakeholders and patients.
Reuters contributed to this article.
This article was translated with the help of artificial intelligence. For more information, please see our Terms of Use.
